Claims surrounding BPC-157 benefits derive exclusively from preclinical animal studies, which regulatory bodies do not accept as sufficient evidence for human therapeutic approval
DOI: Published online: March 18, 2022 1 National Drug Clinical Trial Institution, Second Affiliated Hospital, Army Medical University, Chongqing, China Corresponding author: Jiyin Zhou National Drug Clinical Trial Institution, Second Affiliated Hospital, Army Medical University, Chongqing 400037, China E-mail: [email protected] *Xiaolong Li and Yan Cai contributed equally to this study as first authors
What's the difference between TB-500 and Thymosin Beta-4
Many people use it once a day and some use it twice, applied to clean skin before moisturiser
The companys shipping protocol includes proper packaging and labeling to maintain compound integrity during transport